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electing Patients
or an Implantable
ardioverter-Defibrillator
an the Genie Be
ut Back Into the Bottle?*
uneet Mittal, MD, FACC
ew York, New York
he implantable cardioverter-defibrillator (ICD) has been
hown to be an effective therapy for the prevention of
udden cardiac death (1), an entity that remains a significant
ublic health problem. However, because device implanta-
ion carries risks and is costly, the challenge has been to
dentify patients most likely to derive benefit from ICD
mplantation, especially those patients who have not yet
uffered a clinical event (i.e., a primary prevention cohort).
oward this end, a number of randomized clinical trials
ave evaluated the efficacy of ICD implantation, as assessed
y improvements in overall survival.
See page 288
Left ventricular dysfunction identifies a patient cohort at
articularly high risk for sudden death. As a result, all ICD
rials to date have only included patients with some degree
f left ventricular dysfunction (ejection fraction [EF] 30%
o 40%). Initial trials included only patients with ischemic
eart disease (as evidenced by a previous myocardial infarc-
ion) and required the presence of at least one additional
arker thought to confer high risk, such as the presence of
onsustained ventricular tachycardia. However, ICD im-
lantation was limited to those patients in whom sustained
entricular tachycardia or fibrillation was inducible at elec-
rophysiologic testing (2,3). Although these trials demon-
trated an overwhelming benefit of the ICD, concerns were
aised about the residual risk of arrhythmic events in
atients with a negative electrophysiology study (3). As a
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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oston Scientific and Medtronic.esult, more recent trials have focused on the presence of left
entricular dysfunction, either alone or in combination with
nderlying New York Heart Association (NYHA) func-
ional class II or III congestive heart failure (4,5). Because
hese trials still demonstrate the benefit of ICD implanta-
ion (albeit of a smaller magnitude), current practice guide-
ines recommend ICD implantation in patients with ische-
ic heart disease who are at least 40 days removed from
yocardial infarction, have an EF 30%, with NYHA
unctional class II or III heart failure symptoms while on
ptimal medical therapy (class I indication), or in patients
ith an EF 30% to 35% due to any origin and NYHA
unctional class II or III heart failure symptoms while on
ptimal medical therapy (class IIa indication) (6).
However, concerns have been raised about the increasing
umber of patients needed to treat to save one patient life,
he low likelihood of implanted patients receiving appropri-
te ICD therapy, and the marginal cost-effectiveness of an
pproach that relies predominantly on the presence of left
entricular dysfunction (7–10). Furthermore, population-
ased studies demonstrate that the demographics of patients
urrently undergoing ICD implantation differ significantly
rom those of patients enrolled in the original randomized
linical trials. Specifically, advanced age, the presence of
ongestive heart failure, and noncardiac co-morbid condi-
ions such as renal failure, chronic pulmonary disease,
eripheral vascular disease, and diabetes occur frequently in
atients currently undergoing ICD implantation and ad-
ersely affect prognosis (11).
Therefore, more recently, investigators have sought to
dentify patients with left ventricular dysfunction who may
ot derive benefit from ICD implantation. For example,
uxton et al. (12) recently reported on the limitations of
sing EF alone for predicting arrhythmic death and overall
ortality using data derived from MUSTT (the Multi-
enter Unsustained Tachycardia Trial). This trial enrolled
atients with a previous documented myocardial infarction,
n EF 40%, and nonsustained ventricular tachycardia;
anagement was directed by the results of electrophysi-
logic testing. Using a cohort of 670 patients (either those
n whom no ventricular arrhythmia was inducible or induc-
ble patients randomized to no therapy) in whom data for
YHA heart failure functional class were available, the
uthors identified several variables that predicted overall
ortality. These included EF, the presence of either left
undle branch block or an intraventricular conduction delay,
dvanced heart failure, inducibility of a ventricular tachyar-
hythmia at electrophysiologic testing, increased age, and
resence of atrial fibrillation. As pointed out by the authors,
ost of these variables are readily ascertained noninvasively
n the office setting. Of note, 25% of the patient population
ad none of these additional risk factors; these patients had
2-year mortality of only 5%. These data clearly suggest
hat certain patients are at low risk of death despite having
ignificant left ventricular dysfunction.
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Editorial Comment January 22, 2008:297–9In this issue of the Journal, Goldenberg et al. (13) provide
dditional novel insights from MADIT (Multicenter Au-
omatic Defibrillator Implantation Trial)-II, which enrolled
,232 patients with documented myocardial infarction and
n EF 30%; patients were randomized in a 3:2 ratio to
eceive either an ICD or continue conventional medical
herapy. The authors first identfied a “very high risk” (VHR)
opulation (representing 5% of the overall study cohort),
efined by the presence of underlying renal dysfunction
blood urea nitrogen [BUN] 50 mg/dl and/or creatinine
2.5 mg/dl). (It should be noted that, by design, patients
ith a BUN 70 mg/dl or a creatinine level 3.0 mg/dl
ere specifically excluded in the overall MADIT-II study.)
s compared with non-VHR patients, VHR patients were
lder, had a lower EF, had more advanced heart failure, and
wider QRS duration. The crude 2-year mortality in VHR
atients treated with medical therapy was nearly 50% and
as not improved by ICD implantation.
For the non-VHRpatients, using amultivariate proportional-
azards regression model, the authors identified 5 clinical
ariables that predicted all-cause mortality in patients as-
igned to conventional medical therapy. These included
YHA functional class congestive heart failure II, the
resence of atrial fibrillation (defined as the baseline rhythm
t enrollment), a QRS duration 120 ms, age 70 years,
nd a BUN 26 mg/dl (and, by definition, 50 mg/dl). A
ingle point was assigned to each of thse 5 variables to create
risk score ranging from 0 to 3. Importantly, nearly
ne-third of the study population had none of these risk
actors (a score of 0). These patients had a 2-year mortality
f only 8%; ICD implantation did not further reduce
ortality in this subset of patients. In contrast, patients with
1 risk factor had 4 times the mortality of patients with no
isk factor; ICD implantation in patients with 1 risk
actors was associated with a nearly 50% reduction in
ortality. The benefit was most pronounced in patients
ith 1 or 2 risk factors, a cohort that represented half the
verall study population and in whom sudden death pre-
ominated as the cause of death.
What implications do these findings have on the selection
f patients who are appropriate candidates for ICD implan-
ation? Certainly, these data are applicable only to patients
ith coronary artery disease, history of previous myocardial
nfarction, and left ventricular dysfunction. However, the 5
high-risk” markers identfied by Goldenberg et al. (13)
ppear to be consistent with findings in other clinical
ettings. For example, in a population comprising a pre-
ominantly secondary prevention cohort, Klein et al. (14)
dentfied left ventricular dysfunction (EF 40%), perma-
ent atrial fibrillation, and a QRS duration 150 ms as
ndependent predictors of a recurrence of a ventricular
achyarrhythmia after ICD implantation.
In the context of findings reported by the MUSTT
nvestigators, the analysis of the MADIT-II data by Gold-
nberg et al. (13) confirms that a significant proportion of
atients with an ischemic cardiomyopathy lack other riskactors for sudden death. These patients have a low absolute
isk of death that is not further attentuated by ICD
mplantation. We must keep in mind, however, that data
eing reported are for 2-year mortality risk, which repre-
ents a relatively short period of follow-up. Whether these
ndings persist over longer follow-up periods remains
nknown. Second, although a wide variety of markers have
een used for risk stratification (e.g., signal-averaged elec-
rocardiography, T-wave alternans, heart rate variability), it
ay be that variables readily obtainable in an in-office
etting, such as age, the presence of atrial fibrillation, degree
f heart failure, QRS duration, and degree of renal
ysfunction, may effectively risk stratify patients with an
schemic cardiomyopathy. Of concern, however, is that
hese variables are not static. Rather, patients get older,
o in and out of atrial fibrillation, have exacerbations of
ongestive heart failure, and often have varying renal
unction. The impact of this variability on patient outcome
lso remains undefined.
What is clear is that EF alone is likely not enough when
aking judgements regarding the need for ICD implanta-
ion in an individual patient with an ischemic cardiomyop-
thy. The challenge now before us, however, is to investi-
ate these variables in a prospective manner. As a starting
oint, potential expansion of the ICD Registry (from the
ational Cardiovascular Data Registry) to include informa-
ion on long-term mortality would be very useful in defining
rospectively the prognostic utility of these proposed “high-
isk” variables, especially because these variables are all
aptured within the database. Without having these types of
ata, practice guidelines will remain unchanged and it will
e hard (if not impossible) to deny “eligible” patients the
ption of ICD implantation. It is not always easy to put the
enie back into the bottle.
eprint requests and correspondence: Dr. Suneet Mittal, Divi-
ion of Cardiology, St. Luke’s-Roosevelt Hospital Center, 1111
msterdam Avenue, New York, New York 10025. E-mail:
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